Ocular Therapeutix (OCUL) Given Daily Media Impact Score of 0.14

Media coverage about Ocular Therapeutix (NASDAQ:OCUL) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ocular Therapeutix earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.6293824604599 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the headlines that may have impacted Accern’s rankings:

Shares of Ocular Therapeutix stock traded up $0.12 on Thursday, hitting $6.17. 254,700 shares of the company traded hands, compared to its average volume of 406,583. The company has a quick ratio of 4.91, a current ratio of 4.92 and a debt-to-equity ratio of 0.21. Ocular Therapeutix has a 12-month low of $3.30 and a 12-month high of $8.28. The stock has a market cap of $240.04 million, a P/E ratio of -2.80 and a beta of 1.11.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, meeting the consensus estimate of ($0.37). Ocular Therapeutix had a negative net margin of 2,814.72% and a negative return on equity of 143.32%. The business had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $0.35 million. equities research analysts expect that Ocular Therapeutix will post -1.55 earnings per share for the current fiscal year.

Several brokerages have issued reports on OCUL. Zacks Investment Research raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Tuesday. ValuEngine cut shares of Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a report on Monday, July 2nd. Cantor Fitzgerald set a $22.00 price target on shares of Ocular Therapeutix and gave the company a “buy” rating in a report on Tuesday, August 7th. BidaskClub cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Wednesday, July 4th. Finally, HC Wainwright set a $10.00 price target on shares of Ocular Therapeutix and gave the company a “buy” rating in a report on Monday, July 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Ocular Therapeutix presently has a consensus rating of “Hold” and an average target price of $12.75.

In other Ocular Therapeutix news, insider Antony C. Mattessich acquired 16,900 shares of the firm’s stock in a transaction that occurred on Friday, August 10th. The stock was purchased at an average cost of $6.23 per share, for a total transaction of $105,287.00. Following the completion of the acquisition, the insider now owns 37,900 shares of the company’s stock, valued at approximately $236,117. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Donald Notman acquired 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was acquired at an average price of $6.29 per share, with a total value of $78,625.00. Following the completion of the acquisition, the chief financial officer now directly owns 17,300 shares of the company’s stock, valued at approximately $108,817. The disclosure for this purchase can be found here. Insiders own 15.90% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

Read More: Book Value Of Equity Per Share – BVPS Explained

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply